| EYEPOINT INC. DL-,01 |
| USA |
| Gesundheit |
| US30233G2093 / A2QJRU |
| PV3B (Frankfurt) / EYPT (NASDAQ) |
| FRA:PV3B, ETR:PV3B, PV3B:GR, NASDAQ:EYPT |
| - |
| https://eyepointpharma.co.. |
|
EyePoint Pharmaceuticals Inc. is a specialty biopharmaceutical company focused on developing and commercializing innovative ophthalmic products. Its primary purpose is to treat serious eye disorders, particularly targeting diseases like wet age-relat..
>Volltext.. |
| 941.06 Mio. EUR |
| 699.97 Mio. EUR |
| 27.18 Mio. EUR |
| -208.89 Mio. EUR |
| -200.95 Mio. EUR |
| -2.74 EUR |
| 19.75 Mio. EUR |
| 88.21 Mio. EUR |
| -208.01 Mio. EUR |
| 8.27 |
| -36.1% |
| -56.23% |
| - |
| - |
| - |
| EYEPOINT |
| 05.04.26 |